breakdown (BRBB) offers promise for the treatment of diabetic macular edema. Here, we
demonstrated a reversal of blood–retinal barrier pathology mediated by AAV type 2 (AAV2)
vectors encoding vasoinhibin or soluble VEGF receptor 1 (sFlt-1) when administered
intravitreally to diabetic rats. Efficacy and safety of the AAV2 vasoinhibin vector were tested
by monitoring its effect on diabetes-induced changes in the retinal vascular bed and …